Changeflow GovPing Pharma & Drug Safety Phase I AD-230 Pharmacokinetics Study, Chronic ...
Routine Notice Added Final

Phase I AD-230 Pharmacokinetics Study, Chronic Liver Disease

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected
Email

Summary

The National Library of Medicine's ClinicalTrials.gov registered NCT07521241, a Phase I study evaluating the pharmacokinetics of investigational drug AD-230 in patients with chronic liver disease. The trial collects PK parameters to characterize drug absorption, distribution, metabolism, and excretion in this population. This registry entry documents the study's design, eligibility criteria, and investigator information for public transparency.

What changed

ClinicalTrials.gov published registration NCT07521241 for a Phase I pharmacokinetics study of investigational drug AD-230 in patients with chronic liver disease. The registry entry includes study objectives, eligibility criteria, endpoints, and participating investigator sites. As a public registry requirement under FDA regulations, this entry ensures transparency for clinical research involving human subjects.

Pharmaceutical sponsors conducting early-phase clinical research should ensure their trial registrations remain current and accurately reflect protocol amendments. Clinical investigators reviewing this entry should confirm institutional review board approval status and assess alignment with institutional drug development programs.

What to do next

  1. Monitor ClinicalTrials.gov for study updates

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NLM.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
NLM
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07521241

Who this affects

Applies to
Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug development Clinical research Pharmacokinetics
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.